Clinical Research Details

Descriptive Information
Randomized Multicenter Study to Compare the Effectiveness and Safety of Erlotinib and Pemetrexed as Maintenance Therapy of Advanced Non-Small Cell Lung Cancer

Arafat Tfayli


Clinical Research - Clinical Trials (phase 0, 1,2 3 & 4)  

Phase 2  

Conditions and Keywords
lung cancer
lung cancer,erlotinib,pemetrexed
Study Design
Eligibility and IRB
Min: 18
In Progress

Randomized multi-center prospective study to compare the 12-month effectiveness (survival) and safety of Mirata and Pemitra as maintenance treatment in two groups of patients with locally advanced or metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology, whose disease has not progressed immediately following platinum-based chemotherapy for 4 cycles administered per routine daily practice in the KHCC, the AUBMC, and the KFSHRC.

Eligible patients will be randomized into either the Erlotinib Arm, in which patients will receive Erlotinib 150 mg once daily until disease progression or unacceptable toxic effects, or the Pemetrexed Arm, in which patients will receive Pemetrexed 500 mg/m2 administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxicity.

Maintenance treatment will start within 7 days from the randomization date and 21–42 days from Day 1 of the fourth cycle of induction therapy.

All patients will be followed up until study closure or death.    

1. Age ≥18 years.

2.     Signed written informed consent.

3.     Histologically or cytological diagnosed stage IIIB/IV non-squamous histology NSCLC.

4.     Received platinum based doublet chemotherapy for 4 cycles as first line therapy before this study.

5.     Patients upon enrolment has at least stable disease following the platinum doublet; with documented (confirmed or unconfirmed) radiographic evidence of a tumor response of complete response (CR), partial response (PR), or stable disease (SD) according to RECIST ver 1.1 criteria.

6.     Estimated Life expectancy ≥ 3 months.

7.     ECOG PS 0-2

8.     Adequate organ function.

1.     Age <18 years.

2.     Predominantly squamous cell and/or mixed small cell, non-small cell histology.

3.     Current treatment on another therapeutic clinical study or within the last 30 days of entering the study.

4.     Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or leptomeningeal disease.

5.     Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.

6.     Ongoing cardiac dysrhythmias of NCI CTCAE Grade >2, uncontrolled atrial fibrillation of any grade, or QTc interval >470 msec.

7.     Pregnancy or breastfeeding.

8.     Prior malignancy (other than current NSCLC): patients will not be eligible if they have evidence of active malignancy (other than non-melanoma skin cancer or localized cervical cancer, or localized and presumed cured prostate cancer) within the last 3 years.

9.     Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impose, in the judgment of the investigator and/or sponsor, excessive risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate to enter this study.

10.  Uncontrolled third-space fluid collections.

11.  Progressive brain metastases.

12.  Hypersensitivity to the study drugs.

13.  I e expectancy ≥ 3 months.  of entering the study. e of complete response (CR), or stable disease (SD) according to RECIST critenability to take corticosteroid drugs, folic acid, or vitamin B12.

14. Patients with EGFR-positive, ALK-positive (documented using FISH and/or IHC), or unknown EGFR and ALK test results.